What is the recommended treatment for angiosarcoma of the breast?

Treatment of Angiosarcoma of the Breast

For primary breast angiosarcoma, perform wide surgical excision (mastectomy preferred over breast conservation) followed by adjuvant chemotherapy with taxanes (paclitaxel) or anthracyclines (doxorubicin), as chemotherapy significantly improves survival in this aggressive malignancy.

Surgical Management

Surgery is the cornerstone of treatment for breast angiosarcoma. Mastectomy is the standard surgical approach 1, 2, 3, as breast conservation is associated with significantly higher positive margin rates (OR 3.29) 4. Positive margins are a strong predictor of mortality (HR = 2.37) 4, making complete resection critical.

• Wide excision with negative margins (R0 resection) is mandatory 1
• Mastectomy achieves better local control than lumpectomy for this infiltrative tumor
• For radiation-induced angiosarcoma specifically, consider resurfacing plastic surgical procedures to achieve adequately wide margins 1
• Delayed reconstruction is preferred over immediate reconstruction for large, high-grade tumors, as patients will likely require postoperative radiotherapy and carry significant risk of local recurrence within the first two years 1

Systemic Chemotherapy

The evidence strongly supports adjuvant chemotherapy for breast angiosarcoma:

A 2026 meta-analysis of 436 patients demonstrated that adjuvant chemotherapy was associated with dramatically improved survival (HR = 0.11,95% CI: 0.02-0.45) 2. This represents an 89% reduction in mortality risk.

First-Line Chemotherapy Options:

1. Taxanes (preferred for angiosarcoma): Weekly paclitaxel has high antitumor activity specific to angiosarcoma 5, 6, 5, 7

2. Anthracyclines: Doxorubicin-based regimens are standard first-line treatment for soft tissue sarcomas 5, 7

   • Can use doxorubicin alone or combined with ifosfamide when tumor response is critical and performance status is good

3. Gemcitabine ± docetaxel: Alternative option with demonstrated activity in angiosarcoma 5, 7

Second-Line Options:

• Pazopanib, sorafenib, or regorafenib are recommended as second-line therapy for vascular sarcomas 6, 8
• Liposomal doxorubicin 6
• Propranolol plus vinblastine combination 6

Radiation Therapy

Adjuvant radiotherapy should be considered for large tumors (>5 cm) and/or high-grade tumors with close (<5 mm) or positive margins 1. However, the 2026 meta-analysis found that radiotherapy showed no survival benefit (p = 0.96) 2, suggesting its role is primarily for local control rather than survival improvement.

• Radiotherapy improves local control but not overall survival in breast sarcomas 1
• Neoadjuvant radiotherapy has no role in breast angiosarcoma 1

Treatment Algorithm by Clinical Scenario

Localized, Resectable Disease:

1. Mastectomy with wide margins (R0 resection)
2. Adjuvant chemotherapy (taxanes or anthracyclines)
3. Consider adjuvant radiotherapy if tumor >5 cm, high-grade, or margins <5 mm

Locally Advanced Disease (Surgery Would Be Excessively Morbid):

1. Neoadjuvant chemotherapy (taxanes or anthracyclines) 1
2. Reassess for surgical resection after response
3. Mastectomy if resectable after chemotherapy
4. Consider radiotherapy for residual disease or close margins

Metastatic Disease:

1. First-line: Anthracyclines (doxorubicin ± ifosfamide) or taxanes 5
2. Second-line: Pazopanib, sorafenib, or regorafenib 6, 8
3. Consider gemcitabine-based regimens 6, 7
4. Immune checkpoint inhibitors may be considered in clinical trial settings 6, 7

Prognostic Factors

Tumor grade is the paramount prognostic factor 2:

• Grade 3 vs. Grade 1: HR = 3.7 (nearly 4-fold increased mortality)
• Grade 2 vs. Grade 1: HR = 1.2

Other adverse prognostic factors include:

• Tumor size >5 cm 4
• Positive surgical margins 4
• Older age and higher comorbidity scores 4
• Radiation-induced angiosarcoma (more aggressive biology) 1

Critical Pitfalls to Avoid

1. Do not perform breast conservation surgery unless the tumor is small, well-selected, and negative margins can be confidently achieved—positive margins dramatically worsen survival 4

2. Do not omit adjuvant chemotherapy—the evidence shows an 89% reduction in mortality risk with chemotherapy 2

3. Do not perform immediate breast reconstruction for large, high-grade tumors, as this may compromise adjuvant treatment delivery 1

4. Do not rely on radiotherapy alone for survival benefit—it provides local control but does not improve overall survival 2

5. Ensure multidisciplinary discussion between breast and sarcoma MDTs before surgery, particularly for radiation-induced angiosarcoma 1